Tirzepatide
Two pathways. Greater results. The next generation of medically supervised weight management for women ready to take a more targeted approach.
What Is It
Tirzepatide is a dual agonist — it activates both the GLP-1 and GIP receptors simultaneously, targeting two distinct metabolic pathways at once. It's the medication class behind Mounjaro and Zepbound, compounded at a licensed U.S. pharmacy and prescribed through your Vitality Wellness consultation. Clinical trials have shown Tirzepatide to produce greater average weight loss than GLP-1 single agonists like Semaglutide, making it a compelling option for clients with more significant metabolic or weight management goals.
Who’s It For
Anyone with significant weight management goals who want the most clinically studied option currently available
Clients who have previously tried a GLP-1 single agonist (like Semaglutide) with partial response
Those with insulin resistance, prediabetes, or type 2 diabetes, as Tirzepatide has strong data for blood sugar management
Clients whose provider determines, based on consultation, that a dual-agonist approach is the appropriate starting point
Not appropriate for clients with personal or family history of medullary thyroid carcinoma, MEN2, or pancreatitis — full consultation required
What It Does
Reduces appetite and food preoccupation through GLP-1 receptor activity
Enhances insulin secretion and improves insulin sensitivity through GIP receptor activity
Supports greater reduction in body weight compared to GLP-1 therapy alone in clinical data
Promotes fat mass reduction with greater preservation of lean muscle mass than some other approaches
Improves blood sugar regulation and metabolic markers
May have favorable effects on cardiovascular risk factors
How It Works
GIP (glucose-dependent insulinotropic polypeptide) is a second gut-released hormone that works alongside GLP-1 in metabolic regulation. While GLP-1 primarily suppresses appetite and slows gastric emptying, GIP plays a distinct role in fat tissue metabolism and enhancing insulin secretion from the pancreas. By activating both receptors, Tirzepatide engages a broader metabolic response than GLP-1 agonism alone — supporting greater fat mobilization and potentially better metabolic outcomes.
It's worth noting that Tirzepatide's mechanism around GIP is still an active area of research. What the clinical data shows clearly is that the dual-agonist approach produces meaningfully greater weight loss outcomes in trials, with a side effect profile similar to single GLP-1 agonists.
What To Expect
Tirzepatide is administered as a weekly subcutaneous injection, with a gradual titration schedule beginning at a low dose to support tolerability. Side effects are similar to Semaglutide — primarily GI-related during the titration phase — and typically resolve as the body adjusts. Most clients notice significant appetite reduction within the first 2–4 weeks. Average weight loss in clinical trials reached 15–22% of body weight over approximately 72 weeks at the highest doses, though individual results vary. Your protocol includes regular provider check-ins to monitor progress and adjust.
Best Paired With
Glutathione — liver and detox support during active weight loss
B12 — energy support during caloric deficit
Sculpt — for clients prioritizing lean muscle preservation and body composition alongside weight loss
Erin Zell (Health Coaching) — nutrition and lifestyle support to maximize and sustain results long term
All content is for informational purposes only. Services are available by consultation and provided under the supervision of a licensed medical provider.
All treatments require a Vitality Wellness Consultation. Protocols are personalized and available only with provider authorization. Compounded medications are prescribed based on individual needs and are not FDA-approved. These therapies are not intended to diagnose, treat, cure, or prevent any disease.
Individual results may vary.
To begin, book your Vitality Wellness Consultation by calling 774.202.0677.